ELANIX BIOTECHNOLOGIES AG Inactive Instrument
Elanix Biotechnologies AG Stock Xetra
Equities
ELN
DE000A0WMJQ4
Biotechnology & Medical Research
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 11-12-31 | |
Egon Minar
DFI | Director of Finance/CFO | - | 18-05-28 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marco Christen
CHM | Chairman | - | 20-02-26 |
| Director/Board Member | - | 21-05-03 | |
| Director/Board Member | - | 23-02-09 |
Elanix Biotechnologies AG is a Germany-based provider of solutions for tissue regeneration. The Company develops and commercializes products for acute wound care, dermatological and gynecological applications, and also provides cell technology services. It develops bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts. The Company's product portfolio comprises Gyn-RepAir cream, which contains a Cell Free Protein Complex (CFPC), and which includes various proteins such as collagen and fibronectin, as well as RepAir-A N cream. The Company also produces validated progenitor skin cells used in drug discovery, toxicity testing and cosmetic applications. It is a spin-out from the University Hospital of Lausanne (CHUV) in Switzerland.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
